Ronald Buckman, MD
Sports Medicine · Bolton, CTNPI 1871561092
Payments from drug & device makers
Across 592 payments — averaging $22.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- Novo Nordisk$2K
- Lilly USA, LLC$1K
- AbbVie$1K
- Boehringer Ingelheim$1K
- Amgen$1K
- plus $4K from 30 others
What the payments were for
- Consulting fees$5124%
- Food & beverage$12,97896%
- Education$40%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 81 | $2,428 |
| Novo Nordisk | 98 | $1,624 |
| Lilly USA, LLC | 64 | $1,499 |
| AbbVie(2 entities) | 75 | $1,359 |
| Boehringer Ingelheim | 50 | $1,171 |
| Amgen(2 entities) | 24 | $1,167 |
| Pfizer | 51 | $973 |
| GSK | 45 | $937 |
| Merck | 22 | $405 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 14 | $292 |
| Corcept Therapeutics | 9 | $262 |
| Amneal Pharmaceuticals LLC | 12 | $257 |
| Otsuka America Pharmaceutical, Inc. | 2 | $147 |
| Astellas Pharma US Inc | 6 | $146 |
| Amarin Pharma, Inc. | 6 | $112 |
| Sanofi-aventis U.S. LLC | 4 | $75 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $61 |
| Teleflex LLC | 1 | $58 |
| Sumitomo Pharma America, Inc. | 2 | $57 |
| VBI Vaccine (delaware) Inc. | 3 | $54 |
| Abbott | 2 | $43 |
| Shire North American Group Inc | 2 | $41 |
| Kowa Pharmaceuticals America, Inc. | 2 | $33 |
| Biogen | 1 | $33 |
| Sanofi Pasteur Inc. | 2 | $31 |
| Gilead | 2 | $28 |
| Actelion Pharmaceuticals US, Inc. | 1 | $27 |
| Arbor Pharmaceuticals, Inc. | 1 | $26 |
| Exact Sciences | 1 | $25 |
| Seqirus USA Inc | 1 | $23 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $23 |
| Scilex Pharmaceuticals Inc. | 1 | $17 |
| Vistapharm, Inc. | 1 | $17 |
| Dermira, Inc. | 1 | $15 |
| IBSA Pharma Inc. | 1 | $14 |
| Biohaven Pharmaceuticals, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$13,494 in reported general payments places this provider in the 75th percentile of 65 sports medicine providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 58 | $108,003 |
| JardianceEmpagliflozin | 59 | $92,062 |
| FarxigaDapagliflozin Propanediol | 53 | $67,073 |
| MounjaroTirzepatide | 20 | $34,743 |
| RybelsusSemaglutide | 13 | $32,847 |
| EliquisApixaban | 12 | $20,113 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 11 | $16,875 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 11 | $15,419 |
| Tresiba Flextouch U-200Insulin Degludec | 16 | $10,853 |
| Tresiba Flextouch U-100Insulin Degludec | 11 | $7,505 |
| VascepaIcosapent Ethyl | 13 | $5,054 |
| SynthroidLevothyroxine Sodium | 46 | $4,420 |
| Boostrix TdapDiphth,pertuss(Acell),tet Vac | 28 | $2,575 |
| Levothyroxine Sodium | 334 | $2,456 |
| Rosuvastatin Calcium | 191 | $2,071 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $1,624 | $140,85071 claims |
| Boehringer IngelheimJardiance | $1,171 | $92,06259 claims |
| AstraZenecaFarxiga | $2,428 | $67,07353 claims |
| Lilly USA, LLCMounjaro | $1,499 | $34,74320 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $937 | $32,29422 claims |
| PfizerEliquis | $973 | $20,11312 claims |
| AbbVieSynthroid | $1,359 | $4,42046 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $257 | $2,456334 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 65 sports medicine providers in Connecticut.
Other sports medicine in Bolton
- Augustus MazzoccaFarmington$2.7M
- Michael KaplanMiddlebury$385K
- Robert ArcieroFarmington$269K
- Katherine CoynerFarmington$264K
- Karen SuttonStamford$245K
- Michael KuhnMiddletown$201K
- Joshua FrankNorwalk$78K
- Michael JoyceGlastonbury$73K
- Andrew JimenezNew Haven$73K
- Jordan GruskayBranford$47K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.